Mesoblast Sees Accelerated Path To Market For Revascor In Sickest Heart Failure Patients
Executive Summary
US FDA agrees to plan to seek approval for ‘off the shelf’ cell therapy with Phase II data showing fewer major mucosal bleeding events in end-stage heart failure patients implanted with mechanical assist devices; confirmatory Phase III is set to begin this year.